Chiral Technologies Europe (CTE) announced that it has entered into an exclusive worldwide licensing agreement with the University of Vienna, Austria. According to the agreement, CTE acquired exclusive manufacturing and marketing rights for novel Cinchona alkaloid-based zwitterion-exchange type chiral stationary phases (CSPs), invented and developed by researchers at the University of Vienna. The addition of the new CSPs provides a significant expansion of Chiral Technologies’ well-established portfolio of enantioselective chromatography products.
“The opportunity to collaborate with Professor Lindner and his renowned research team at the University of Vienna on the commercialization of this new stationary phase fits nicely within our broader strategy to expand our position in supplying new chirality tools to the life science industry,” said Dieter Heckmann, President and CEO of CTE. “This licensing agreement demonstrates our continued commitment to deliver the best solutions to the global market.”
The zwitterion-exchange type CSPs separate a broad range of ionizable chiral analytes, ranging from acidic and basic molecules to zwitterionic molecules that bear basic and acidic moieties in the same molecule. It has been adapted for direct enantiomer resolution of natural and synthetic free a-, b-, g-amino acids without requiring pre-column derivatization. In addition, chiral zwitterionic peptides and peptomimetics can be separated into their respective stereoisomers. The new selectors can be used in liquid chromatography and supercritical fluid chromatography modes with mobile phases that are compatible with all LC/MS applications.